Xiong Lihua, Cheng Jian
Department of Dermatology, Cheng Du Xinjin District Hospital of Traditional Chinese Medicine, Chengdu, China.
Department of Chinese Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Front Oncol. 2025 May 1;15:1519592. doi: 10.3389/fonc.2025.1519592. eCollection 2025.
Immunotherapy has transformed the landscape of melanoma treatment, offering significant extensions in survival for many patients. Despite these advancements, nearly 50% of melanoma cases remain resistant to such therapies, highlighting the need for novel approaches. Emerging research has identified lipid metabolism reprogramming as a key factor in promoting melanoma progression and resistance to immunotherapy. This reprogramming not only supports tumor growth and metastasis but also creates an immunosuppressive environment that impairs the effectiveness of treatments such as immune checkpoint inhibitors (ICIs). This review delves into the intricate relationship between lipid metabolism and immune system interactions in melanoma. We will explore how alterations in lipid metabolic pathways contribute to immune evasion and therapy resistance, emphasizing recent discoveries in this area. Additionally, we also highlights novel therapeutic strategies targeting lipid metabolism to enhance immune checkpoint inhibitor (ICI) efficacy.
免疫疗法已经改变了黑色素瘤的治疗格局，为许多患者带来了显著的生存期延长。尽管有这些进展，但仍有近50%的黑色素瘤病例对此类疗法耐药，这凸显了采用新方法的必要性。新兴研究已确定脂质代谢重编程是促进黑色素瘤进展和对免疫疗法耐药的关键因素。这种重编程不仅支持肿瘤生长和转移，还营造了一种免疫抑制环境，削弱了免疫检查点抑制剂（ICI）等治疗方法的有效性。本综述深入探讨黑色素瘤中脂质代谢与免疫系统相互作用之间的复杂关系。我们将探究脂质代谢途径的改变如何导致免疫逃逸和治疗耐药，重点介绍该领域的最新发现。此外，我们还强调了针对脂质代谢以提高免疫检查点抑制剂（ICI）疗效的新型治疗策略。
